Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.27 is 87% above its 5-year average of -2.11, near the high end of its 5-year range (-5.64–0.29).
88.24% above its 12-month average of -2.29.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.24.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T13:30:31.741Z. Historical observations retain their original dates. Historical series through 2022-05-05.
EARNINGS PER SHARE (EPS)
-0.27
EARNINGS PER SHARE (EPS) AVG TTM
-2.29
EARNINGS PER SHARE (EPS) AVG 3Y
-2.81
EARNINGS PER SHARE (EPS) AVG 5Y
-2.11
EARNINGS PER SHARE (EPS) AVG 10Y
-0.27
EARNINGS PER SHARE (EPS) AVG 15Y
0.58
EARNINGS PER SHARE (EPS) AVG 20Y
0.91
CURRENT VS TTM AVG
+88.24%
CURRENT VS 3Y AVG
+90.40%
CURRENT VS 5Y AVG
+87.19%
CURRENT VS 10Y AVG
-0.34%
CURRENT VS 15Y AVG
-146.93%
CURRENT VS 20Y AVG
-129.74%
Anika Therapeutics, Inc.
Market Cap
$264.05M
Earnings Per Share (EPS)
-0.27
TTM Avg
-2.29
3Y Avg
-2.81
5Y Avg
-2.11
Market Cap
$260.11M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.82
3Y Avg
-2.37
5Y Avg
-2.68
Market Cap
$266.62M
Earnings Per Share (EPS)
-3.74
TTM Avg
-2.75
3Y Avg
-2.51
5Y Avg
-2.60
Market Cap
$269.80M
Earnings Per Share (EPS)
-1.04
TTM Avg
-0.86
3Y Avg
-1.57
5Y Avg
-1.50
Market Cap
$261.48M
Earnings Per Share (EPS)
-0.99
TTM Avg
-0.90
3Y Avg
-0.84
5Y Avg
-0.86
Market Cap
$252.90M
Earnings Per Share (EPS)
-2.23
TTM Avg
-2.66
3Y Avg
-2.57
5Y Avg
-2.57
Market Cap
$276.82M
Earnings Per Share (EPS)
-0.54
TTM Avg
-0.72
3Y Avg
-0.78
5Y Avg
-0.86
Market Cap
$249.82M
Earnings Per Share (EPS)
-1.54
TTM Avg
-1.32
3Y Avg
-0.98
5Y Avg
-0.74
Market Cap
$248.92M
Earnings Per Share (EPS)
-0.57
TTM Avg
-0.79
3Y Avg
-0.77
5Y Avg
-0.98
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | $264.05M | -0.27 | -2.29 | -2.81 | -2.11 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $260.11M | -0.48 | -0.82 | -2.37 | -2.68 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $266.62M | -3.74 | -2.75 | -2.51 | -2.60 |
| Century Therapeutics, Inc. (IPSC)vs › | $269.80M | -1.04 | -0.86 | -1.57 | -1.50 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $261.48M | -0.99 | -0.90 | -0.84 | -0.86 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $252.90M | -2.23 | -2.66 | -2.57 | -2.57 |
| AC Immune S.A. (ACIU)vs › | $276.82M | -0.54 | -0.72 | -0.78 | -0.86 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $249.82M | -1.54 | -1.32 | -0.98 | -0.74 |
| InflaRx N.V. (IFRX)vs › | $248.92M | -0.57 | -0.79 | -0.77 | -0.98 |
| Invivyd, Inc. (IVVD)vs › | $251.06M | -0.39 | -0.86 | -1.43 | -1.56 |
Trailing EPS (TTM)
$-0.27
Forward EPS (Est.)
$1.05
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.76 |
| 2024-12-31 | -3.83 |
| 2023-12-31 | -5.64 |
| 2022-12-31 | -1.02 |
| 2021-12-31 | 0.29 |
| 2020-12-31 | -1.69 |
| 2019-12-31 | 1.93 |
| 2018-12-31 | 1.30 |
| 2017-12-31 | 2.18 |
| 2016-12-31 | 2.22 |
| 2015-12-31 | 2.06 |
| 2014-12-31 | 2.61 |
| 2013-12-31 | 1.46 |
| 2012-12-31 | 0.89 |
| 2011-12-31 | 0.65 |
| 2010-12-31 | 0.34 |
| 2009-12-31 | 0.32 |
| 2008-12-31 | 0.32 |
| 2007-12-31 | 0.55 |
| 2006-12-31 | 0.43 |
| 2005-12-31 | 0.57 |
| 2004-12-31 | 0.98 |
| 2003-12-31 | 0.08 |
| 2002-12-31 | -0.31 |
| 2001-12-31 | -0.68 |
| 2000-12-31 | 0.02 |
| 1999-12-31 | -0.26 |
| 1998-12-31 | 0.38 |
| 1997-12-31 | 0.60 |
| 1996-12-31 | -0.56 |
(FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown Quote observation: 2026-10-06T13:30:31.741Z. Historical observations retain their original dates. Historical series through 2019-02-26.
